VOR logo

VOR BIOPHARMA INC

VORNASDAQ
🏆 #2383 by market capUS Equity
$323.57▲ $4.89 (+1.51%)
Simulated price
🔔
Track VOR
Get earnings, price moves & breaking news on Telegram
Track
24h▲ 1.5%
7d—
14d—
30d—
ytd—
1y—
🏦Market Cap
$1.15B
Small Cap
📈Revenue Growth (YoY)
—
📊Gross Margin
—
💵FCF Margin
—
⚖️P/S Ratio
—
Otter Score
48
Weak
No chart data available for VOR.

Trading Snapshot

Day Range
$322.32 – $327.23
52-Week Range
$6.50 – $49.95
Volume
$3.17B
Avg Volume
$2.22B
Shares Outstanding
54.2M
Next Earnings
Nov 27, 2026

Fundamentals Snapshot

Annual Revenue
$93M
Last Q Revenue
$21M
P/E Ratio
1.8
P/S Ratio
—
EPS (TTM)
$-43.00
Dividend Yield
—
Dilution (1yr)
+187.4%

Why Investors Own VOR

  • ✓High-growth profile — revenue up +41.8% YoY with expanding US Equity exposure.
  • ✓Healthy economics — 40% gross margin and 9% free-cash-flow margin.
  • ✓New products and segments could unlock additional revenue streams.
⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

VOR logo

VOR BIOPHARMA INC

VOR
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$0▲ +0.0% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
−$372M▲ +206.7% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
−$144M▲ +43.8% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
9.9M▲ +187.4% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
$393M▲ +$343M YoY
StockOtter · stockotter.space

About VOR BIOPHARMA INC

Vor Biopharma, Inc. is a clinical-stage biotechnology firm dedicated to developing innovative engineered hematopoietic stem cell (eHSC) therapies for individuals battling cancer. Its lead product candidate, VOR33, is an eHSC therapy currently undergoing Phase 1/2 clinical trials. VOR33 is designed to target acute myeloid leukemia (AML) and various other hematological malignancies. A key feature of VOR33's eHSCs is their engineered absence of the CD33 protein, which is commonly found on AML blood cancer cells. The company's eHSC platform is intended to enable a range of targeted blood cancer treatments, including CAR-T cell therapies, bispecific antibodies, and antibody-drug conjugates. Vor Biopharma has established a partnership with Akron BioProducts for the development and manufacturing of cGMP nucleases. Established in 2015, the company's headquarters are located in Cambridge, Massachusetts.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)
💎Quality★★★★★
🚀Growth★★★★★
⚖️Valuation★★★★★
⚡Momentum★★★★★
💧Dilution★★★★★
Overall Score
Weak
48/100

Analyst Price Target

ⓘ
Average Target
$408.76
▲ +26.3% Upside
High Target$509.50
Low Target$351.76
Based on 13 analysts

Latest News & Updates

🚀
Bloomberg·2h ago

VOR BIOPHARMA INC tops quarterly estimates as demand accelerates

Revenue grew double digits with management guiding above consensus; margins continued to expand.

🛰️
CNBC·5h ago

Analysts lift VOR price targets on improving margins

Several firms raised targets, citing stronger free cash flow and a healthier backlog.

🌌
CNBC·1d ago

VOR BIOPHARMA INC announces new agreement to expand its footprint

The move broadens the company’s reach and could add incremental revenue over the next year.